{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 121,
  "pageCount": 239,
  "prevPage": 120,
  "nextPage": 122,
  "slideType": "testimonial",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses direct quotes to frame Nevro as a 'one-trick pony' lacking sophistication compared to competitors.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/121",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-121",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Nevro “still feels like a boutique” one-trick pony that’s “not really as sophisticated as they say they are.”",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b341-b071d9c921db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "A senior Nevro ex-executive provided a key reason why growth hit a wall: the legacy SCS incumbents – Medtronic, Boston Scientific, and Abbott – who were asleep at the wheel when Nevro launched in 2015, have quickly caught up, while Nevro “still feels like a boutique” one-trick pony that’s “not really as sophisticated as they say they are.” A KOL provided identical feedback: Nevro is a “one-trick pony” and that everyone now offers paresthesia-free stimulation.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15add36a-1a3e-4594-9103-095a8d1045f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.83,
        "x": 0.11,
        "y": 0.41
      },
      "kind": "quote",
      "text": "We embarrassed the legacy competition but over time that forced them to create new platforms, software, better technology, better interfaces, quicker trial times. They’ve done a lot more for their customers. Nevro still feels like a boutique company. They’re not really as sophisticated as they say they are. When you go to North American Neuromodulation Society meeting every January, you’re seeing an amazing amount of new technology. All the other companies create different types of platforms for different patients. They have optionality, which is a superior sales tactic with the patient saying, “Hey, this didn’t work, but I have other frequencies and waveforms for you and I have this and this and this.”” – Senior Nevro ex-executive",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d049005-e18d-4c2b-b18c-fd146beb2a2d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.83,
        "x": 0.11,
        "y": 0.73
      },
      "kind": "quote",
      "text": "Nevro disrupted the industry with high frequency. Then everyone developed sub-threshold paresthesia-free waveforms. Now companies who don’t even have high frequency have these waveforms. There are lots of competitor pipelines. They’re a one-trick pony. They’re not versatile. That I truly believe. It’s hard to tell a difference clinically.” – High volume KOL",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a608cfc-1652-4313-817c-facce18fc799",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“We embarrassed the legacy competition but over time that forced them to create new platforms, software, better technology, better interfaces, quicker trial times. They’ve done a lot more for their customers. Nevro still feels like a boutique company. They’re not really as sophisticated as they say they are. When you go to North American Neuromodulation Society meeting every January, you’re seeing an amazing amount of new technology. All the other companies create different types of platforms for different patients. They have optionality, which is a superior sales tactic with the patient saying, ‘Hey, this didn’t work, but I have other frequencies and waveforms for you and I have this and this and this.’” — Senior Nevro ex-executive; “Nevro disrupted the industry with high frequency. Then everyone developed sub-threshold paresthesia-free waveforms. Now companies who don’t even have high frequency have these waveforms. There are lots of competitor pipelines. They’re a one-trick pony. They’re not versatile. That I truly believe. It’s hard to tell a difference clinically.” — High volume KOL",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b341-b711138b8847",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdb0037c-fbd1-4808-884a-7be6e7ae79f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.88,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "9. Nevro’s current predicament – a one-tick pony stuck in a ditch – and drivers of its ongoing growth collapse",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9647e157-c3f0-4627-8692-b294696c6ab8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b58968a-c957-4f93-aeb2-ad6d52a4d87d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "c3647620-6d7f-48bc-b642-69350f090a0b",
      "evidence": "Uses expert testimony to validate the thesis.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}